Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1)
Phase of Trial: Phase I/II
Latest Information Update: 10 Apr 2019
Price : $35 *
At a glance
- Drugs ALT 803 (Primary) ; Bintrafusp alfa (Primary) ; Epacadostat (Primary) ; MVA brachyury TRICOM vaccine (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms QuEST1
- 05 Jun 2018 Trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2018 According to a Bavarian Nordic media release, data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018.
- 04 May 2018 Planned initiation date changed from 1 May 2018 to 9 May 2018.